Clinical Study Report (CSR) Template

ICH-E3 Format

---

TITLE PAGE

Study Title: [Full descriptive title including compound, indication, phase]

Protocol Number: [Sponsor protocol number]
Protocol Version: [Final protocol version and date]

Sponsor: [Company name and address]
Compound/Drug Name: [Generic and proprietary names, compound code]
Indication: [Therapeutic area and specific indication studied]

Study Phase: [I / II / III / IV]
Study Type: [Interventional / Observational]

Report Date: [MM/DD/YYYY]
Report Version: [Version number]

Medical Expert: [Name, MD, Title]
Biostatistician: [Name, PhD, Title]

Confidentiality Statement: "This document contains confidential information belonging to [Sponsor]. It may not be reproduced or distributed without permission."

---

SYNOPSIS

Title: [Abbreviated title]

Protocol Number: [Number]
Study Phase: [Phase]
Study Period: [Start date - End date]

Study Objectives

Primary Objective: [State primary objective clearly and concisely]

Secondary Objectives:

• [Secondary objective 1]
• [Secondary objective 2]

Methodology

Study Design: [Randomized, double-blind, placebo-controlled, parallel-group, etc.]

Study Population:

• Target population: [Patient population]
• Key inclusion criteria: [Main criteria]
• Key exclusion criteria: [Main criteria]

Sample Size:

• Planned: [N participants]
• Randomized: [N participants]
• Completed: [N participants]

Treatment:

• Treatment A: [Drug name, dose, route, frequency]
• Treatment B: [Comparator/placebo]
• Treatment duration: [Weeks/months]
• Follow-up duration: [Weeks/months]

Endpoints:

Primary:

• [Primary endpoint definition and timepoint]

Secondary:

• [Secondary endpoint 1]
• [Secondary endpoint 2]

Statistical Methods: [Brief description of analysis approach, significance level, handling of multiplicity]

Results

Participant Disposition:

• Screened: [N]
• Randomized: [N Treatment A, N Treatment B]
• Completed: [N Treatment A, N Treatment B]
• Discontinued: [N overall, % - main reasons]

Demographics and Baseline: [Summary of key baseline characteristics, comparability across groups]

Efficacy Results:

Primary Endpoint:

• [Result for Treatment A vs B, effect size, 95% CI, p-value]

Secondary Endpoints:

• [Results for each secondary endpoint]

Safety Results:

• Any AE: [% Treatment A vs B]
• Treatment-related AE: [% Treatment A vs B]
• Serious AE: [% Treatment A vs B]
• Discontinuations due to AE: [% Treatment A vs B]
• Deaths: [N Treatment A vs B]
• Common AEs (≥5%): [List with percentages]

Conclusions

[Overall conclusions regarding efficacy and safety, benefit-risk assessment]

---

TABLE OF CONTENTS

[Detailed table of contents with page numbers]

---

LIST OF ABBREVIATIONS

Abbreviation	Definition
AE	Adverse Event
ANCOVA	Analysis of Covariance
CI	Confidence Interval
CSR	Clinical Study Report
FAS	Full Analysis Set
GCP	Good Clinical Practice
ICF	Informed Consent Form
ITT	Intent-to-Treat
PP	Per-Protocol
SAE	Serious Adverse Event
SD	Standard Deviation
[Add study-specific abbreviations]

---

ETHICS (Section 2)

2.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB)

[List of all IECs/IRBs that approved the study]

Site Number	Institution	IRB/IEC Name	Approval Date
001	[Institution]	[IRB name]	[MM/DD/YYYY]

2.2 Ethical Conduct of the Study

This study was conducted in accordance with:

• ICH Good Clinical Practice (GCP) E6(R2)
• Declaration of Helsinki (current version)
• Applicable regulatory requirements
• Sponsor Standard Operating Procedures

2.3 Patient Information and Consent

Informed consent was obtained from all participants before any study-specific procedures. The informed consent process included:

• Written information about study purpose, procedures, risks, and benefits
• Opportunity to ask questions
• Voluntary participation with right to withdraw
• Signatures of participant and person obtaining consent
• Copy provided to participant

---

INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE (Section 3)

3.1 Investigators and Study Centers

[Table listing all investigators, sites, and enrollment]

Site No.	Investigator	Institution	City, Country	Subjects Enrolled
001	[Name, MD]	[Institution]	[City, Country]	[N]

Coordinating Investigator: [Name, if applicable]

3.2 Study Administrative Structure

Sponsor:

• Medical Monitor: [Name, credentials]
• Project Manager: [Name]
• Biostatistician: [Name, credentials]

Contract Research Organization (CRO): [Name, if applicable]

• [Responsibilities]

3.3 Responsibilities of Parties Involved

[Description of sponsor, investigator, CRO, DSMB responsibilities]

---

INTRODUCTION (Section 4)

4.1 Background

[Detailed background on disease/condition, unmet medical need, treatment landscape]

4.2 Nonclinical Studies

[Summary of relevant preclinical pharmacology, toxicology, and safety findings]

4.3 Previous Clinical Studies

[Summary of prior clinical experience with investigational product]

4.4 Study Rationale and Objectives

[Justification for conducting this study, specific objectives]

---

STUDY OBJECTIVES AND PLAN (Section 5)

5.1 Objectives and Endpoints

Primary Objective: [Objective statement]

Primary Endpoint: [Detailed endpoint definition, measurement method, timepoint]

Secondary Objectives:

1. [Objective]
2. [Objective]

Secondary Endpoints:

1. [Endpoint definition]
2. [Endpoint definition]

5.2 Study Design

[Detailed description of study design with diagram if helpful]

Design Type: [Parallel, crossover, factorial, etc.] Blinding: [Double-blind, open-label, etc.] Randomization: [1:1, 2:1, stratified, etc.] Duration: [Treatment period, follow-up period]

Study Schema: [Flow diagram showing screening, randomization, treatment periods, follow-up]

5.3 Study Population

Key Inclusion Criteria:

1. [Criterion]
2. [Criterion]

Key Exclusion Criteria:

1. [Criterion]
2. [Criterion]

5.4 Treatments

Investigational Product:

• Name: [Generic, trade, code]
• Formulation: [Tablet, capsule, injection]
• Dose: [Dose and regimen]
• Route: [PO, IV, SC, etc.]
• Packaging and labeling: [Description]

Comparator: [Similar details for comparator or placebo]

Concomitant Medications: [Permitted and prohibited medications]

5.5 Sample Size Determination

Target Sample Size: [N per group, N total]

Justification:

• Assumed effect size: [Value]
• Variability (SD): [Value]
• Type I error (α): [0.05]
• Power (1-β): [80% or 90%]
• Expected dropout rate: [%]
• Two-sided test

5.6 Statistical Analysis Plan

Analysis Populations:

• Full Analysis Set (FAS): [Definition]
• Per-Protocol Set (PPS): [Definition]
• Safety Analysis Set: [Definition]

Statistical Methods:

• Primary endpoint: [Method - e.g., ANCOVA with baseline as covariate]
• Secondary endpoints: [Methods]
• Handling of missing data: [Approach]
• Multiplicity adjustment: [Method if applicable]
• Interim analyses: [If planned]

Significance Level: α = 0.05 (two-sided)

---

STUDY PATIENTS (Section 6)

6.1 Disposition of Patients

Participant Flow (CONSORT Diagram):

[Include detailed CONSORT diagram showing screening through analysis]

Summary Table:

Category	Treatment A	Treatment B	Total
Screened	N	N	N
Screen failures	N (%)	N (%)	N (%)
Randomized	N	N	N
Received treatment	N (%)	N (%)	N (%)
Completed	N (%)	N (%)	N (%)
Discontinued	N (%)	N (%)	N (%)
- Adverse event	N (%)	N (%)	N (%)
- Lack of efficacy	N (%)	N (%)	N (%)
- Lost to follow-up	N (%)	N (%)	N (%)
- Withdrawal of consent	N (%)	N (%)	N (%)
- Other	N (%)	N (%)	N (%)

6.2 Protocol Deviations

Major Protocol Deviations: [Summary of major deviations, impact on data, subjects affected]

Important Protocol Deviations by Category:

Deviation Type	Treatment A	Treatment B	Total
Inclusion/exclusion criteria	N (%)	N (%)	N (%)
Dosing errors	N (%)	N (%)	N (%)
Prohibited medications	N (%)	N (%)	N (%)
Missed visits	N (%)	N (%)	N (%)

---

(Continues with sections 7-14 following ICH-E3 structure...)

---

Note: This is an abbreviated template. A complete CSR following ICH-E3 is typically 50-300 pages with extensive appendices. Key sections to complete:

• Section 7: Efficacy Evaluation
• Section 8: Safety Evaluation
• Section 9: Discussion and Overall Conclusions
• Section 10: Tables, Figures, and Graphs
• Section 11: References
• Section 12-14: Appendices (Protocol, CRFs, Investigator list, etc.)